Satoshi Iwabuchi

Satoshi Iwabuchi

Auto-generated profile, based on publicly available information

Satoshi Iwabuchi

Toho University Ohashi Medical center, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2016 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
MIMasashi Ishii
Masashi Ishii
MHMorito Hayashi
Morito Hayashi
FYFumihiko Yagi
Fumihiko Yagi
KSKenichiro Sato
Kenichiro Sato
GTGoji Tomita
Goji Tomita
SISatoshi Iwabuchi
Satoshi Iwabuchi
When internal carotid artery stenosis is accompanied by ocular ischemic syndrome, intervention is recommended to prevent irreversible visual loss. In this study, we used laser speckle flowgraphy to measure the ocular microcirculation in the optic nerve head before and after carotid artery stenting (CAS) of 40 advanced internal carotid stenosis lesions from 37 patients. The aim was to investigate the relationship between ocular microcirculation and the direction of ophthalmic artery blood flow obtained by angiography. We found that there was a significant increase in blood flow after CAS (P=0.003). Peak systolic velocity as an indicator of the rate of stenosis was also significantly higher in the group with retrograde/undetected flow of the ophthalmic artery than in the group with antegrade flow (P=0.002). In all cases where retrograde flow of the ophthalmic artery was observed before stenting, the flow changed to antegrade after stenting. Through the use of laser speckle flowgraphy, this study found that CAS can improve ocular microcirculation. Furthermore, while patients displaying retrograde flow of the ophthalmic artery before stenting have a poor prognosis, CAS corrected the flow to antegrade, suggesting that visual loss can be prevented by improving the ocular microcirculation.

1 January 2010 in Neurologia medico-chirurgica
Verified
Journal Article
Open access
NSNorihiko Saito
Norihiko Saito
KAKazuya Aoki
Kazuya Aoki
TSTakatoshi Sakurai
Takatoshi Sakurai
KIKeisuke Ito
Keisuke Ito
MHMorito Hayashi
Morito Hayashi
SISatoshi Iwabuchi
Satoshi Iwabuchi
Two patients were treated for intracranial infections involving methicillin-resistant Staphylococcus aureus (MRSA). A 30-year-old woman was admitted to our hospital for intracerebral hemorrhage related to arteriovenous malformation. After decompressive craniectomy, the patient developed an epidural abscess. MRSA was isolated from the pus culture. The infection did not improve after intravenous vancomycin (VCM) administration for 15 days. However, after administration of linezolid (LZD) for 14 days, the infection had improved, and the white blood cell count and C-reactive protein values had normalized. A 53-year-old woman had previously undergone 3 operations for craniopharyngioma before the age of 35 years. She was admitted to our hospital with fever and disturbance of consciousness. Magnetic resonance imaging with contrast medium revealed a brain abscess caused by MRSA. After 14 days of intravenous administration of VCM, the infection had not improved and intravenous administration of LZD was initiated. After administration of LZD for 14 days intravenously and 14 days orally, the infection had improved, and the white blood cell count and C-reactive protein values had normalized. VCM is highly effective against MRSA infection, but penetration into the central nervous system (CNS) is poor. LZD has good CNS penetration, so should be considered for secondline antibiotic therapy for VCM-resistant intracranial MRSA infection.

1 July 2017 in Cancer Research
Verified
Journal Article
Open access
NSNorihiko Saito
Norihiko Saito
KAKazuya Aoki
Kazuya Aoki
NHNozomi Hirai
Nozomi Hirai
SFSatoshi Fujita
Satoshi Fujita
JIJunya Iwama
Junya Iwama
SISatoshi Iwabuchi
Satoshi Iwabuchi
Glioblastoma, the most common adult glioma, is associated with a dismal prognosis. Treatment with bevacizumab has not significantly prolonged overall patient survival times. Glioblastoma resistance to angiogenesis inhibitors is attributed to multiple interacting mechanisms. We have thus embarked on a comprehensive effort to detecting expression signatures that are associated with response to the therapy and these signatures may allow prospective selection of patients with high likelihood of responding to therapy. Notch signaling pathway is an evolutionarily conserved pathway that plays an important role in multiple cellular and developmental processes including cell fate decision, differentiation, proliferation, survival, angiogenesis and migration. Analysis of The Cancer Genome Atlas expression dataset identified a group (43.9%) of tumors with proneural signature showing high Notch pathway activation. In this study, we compared CD133, Notch, and VEGF expressions in histological sections of primary and recurrent glioblastomas after radiotherapy and chemotherapy. Tumor samples were collected from 27 patients at the time of tumor recurrence. We used immunohistochemical techniques to compare expression of CD133, Notch-1 and VEGF. Expressions of CD133-, Notch-1-, and VEGF-positive glioma cells were higher in recurrent glioblastoma after radiotherapy and chemotherapy. To determine the clinical importance of Notch-1 expression in glioblastoma, we analyzed 15 patients who had received bevacizumab therapy followed by a second surgery at recurrence. OS was significantly longer in cases with Notch-1 negativity (8.8 months) than in those with Notch-1 positivity (6.8 months). Electron microscopic observation of two autopsy cases revealed the effects of blood vessel normalization in Notch-1 positive glioblastoma. Electron microscopic images confirmed the presence of pericytes surrounding the vascular endothelium. Autopsied tumors exhibited marked proliferation of Notch-1 and VEGF positive cells around vessels. In tumor angiogenesis, vascular endothelial growth factor and Notch signaling induce sprouting angiogenesis and recruitment of vascular endothelial cells such as tip cells, stalk cells, and phalanx cells. Fully mature phalanx cells are in close contact with pericytes. These findings indicate that bevacizumab treatment promotes vascular normalization by recruiting mature pericytes and associated with resistance to bevacizumab therapy in glioblastoma with high Notch pathway activation. Citation Format: Norihiko Saito, Kazuya Aoki, Nozomi Hirai, Satoshi Fujita, Junya Iwama, Masashi Ikota, Haruo Nakayama, Morito Hayashi, Keisuke Ito, Takatoshi Sakurai, Satoshi Iwabuchi. Notch pathway activation predicts resistance to bevacizumab therapy in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 774. doi:10.1158/1538-7445.AM2017-774

1 January 2010 in Japanese Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
KIKeisuke Ito
Keisuke Ito
JHJunya Hanakita
Junya Hanakita
TTToshiyuki Takahashi
Toshiyuki Takahashi
MMManabu Minami
Manabu Minami
YKYoshihiro Kitahama
Yoshihiro Kitahama
SISatoshi Iwabuchi
Satoshi Iwabuchi
特発性腰椎硬膜外脂肪腫症はまれである.今回われわれは,外科治療を行った4例を経験した.4例の患者はすべて男性で,平均年齢は65.3歳,平均BMIは27.9kg/m^2,来院時JOAスコアは平均16.3/29点,病悩期間は平均35.0ヵ月あった.症状としては,馬尾性間欠性跛行をいずれの症例も呈していた.3例は他の腰椎変性疾患を伴っていた.MRIやCTMでのYサインは4例全例において認められ,1例においてdynamic myelographyが診断に有用であった.治療はすべて患者に椎弓切除による脂肪摘出が施行され症状の改善を認めたが,1例に7ヵ月後foraminotomyを追加した.特発性腰椎硬膜外脂肪腫症の診断には画像の詳細な検討が必要であり,外科的除圧術は症状の改善に有効と考えられた.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
NSNorihiko Saito
Norihiko Saito
NHNozomi Hirai
Nozomi Hirai
NKNaoki Kushida
Naoki Kushida
SSSho Sato
Sho Sato
YHYu Hiramoto
Yu Hiramoto
SISatoshi Iwabuchi
Satoshi Iwabuchi
Glioblastoma is the most common and aggressive primary brain tumor, and even with the best treatment, the tumor repeatedly recurs and grows, eventually invading the entire brain. There are few reports on the pathogenesis and pathological search in the terminal stage of glioblastoma. In this study, we report the pathological analysis of glioblastoma cases that we were able to perform from initial treatment to confirmation of death at our hospital. We analyzed 26 glioblastoma cases (including 18 autopsied cases) treated at our hospital from initial treatment to death. The mean age of the 26 patients was 60.7 years, and the mean overall survival was 16.7 months. The duration of clinical symptoms was 36.2 days from coma to death, and 12 days from the appearance of respiratory depression to death. Psychiatric symptoms and central fever were observed in patients with intrathecal dissemination. Steroids and antiepileptic drugs were often continued after completion of active treatment. Patients with intrathecal dissemination progressed rapidly and presented with a variety of symptoms, including psychiatric symptoms, headache, neck pain, and central fever. In addition, there was a case of diffuse infiltration from the brain parenchyma to the periventricular area in a patient treated with bevacizumab, suggesting the possibility of a change in the form of recurrence. In the terminal stage of glioblastoma, hypoxemia due to disturbance of respiratory center progresses from impaired consciousness to death. Convulsive seizures are rare in the dying stage, and continuation of antiepileptic drugs should be considered. Although many patients develop from local recurrence, it was suggested that new treatment may change the mode of recurrence or alter the trait of tumor cells. In recent years, the number of patients receiving home care and end-of-life care has been increasing due to the improvement of medical systems such as home care. Further investigation of the pathophysiology is necessary for better end-of-life care. Citation Format: Norihiko Saito, Nozomi Hirai, Naoki Kushida, Sho Sato, Yu Hiramoto, Satoshi Fujita, Haruo Nakayama, Morito Hayashi, Keisuke Ito, Takatoshi Sakurai, Satoshi Iwabuchi. Clinical feature of end-stage cerebral glioblastomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5259.

1 September 2023 in Brain Hemorrhages
Verified
Journal Article
Open access
SSSho Sato
Sho Sato
SFSatoshi Fujita
Satoshi Fujita
YHYu Hiramoto
Yu Hiramoto
MHMorito Hayashi
Morito Hayashi
NKNaoki Kushida
Naoki Kushida
SISatoshi Iwabuchi
Satoshi Iwabuchi